Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
RETFound: the development and use of a foundation model for retinal imaging
Author Affiliations & Notes
  • Pearse Andrew Keane
    Moorfields Eye Hospital, London, London, ENGLAND, United Kingdom
  • Footnotes
    Commercial Relationships   Pearse Keane Novartis, Boehringer-Ingleheim, Apellis, Abbvie, Topcon, Zeiss, RetinAI, Roche, Bitfount, Code C (Consultant/Contractor), Big Picture Medical, Code I (Personal Financial Interest), Google, Code P (Patent), Bayer, Code R (Recipient)
  • Footnotes
    Support  UK Research & Innovation Future Leaders Fellowship (MR/T019050/1)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3874. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pearse Andrew Keane; RETFound: the development and use of a foundation model for retinal imaging. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3874.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Ophthalmology is among the most technology-driven of the all the medical specialties, with treatments utilizing high-spec medical lasers and advanced microsurgical techniques, and diagnostics involving ultra-high resolution imaging. Ophthalmology is also at the forefront of many trailblazing research areas in healthcare, such as stem cell therapy, gene therapy, and - most recently - artificial intelligence. In my presentation, I will describe the development of RETFound, a foundation model for ophthalmology. RETFound was trained on 1.6 million retinal images using self-supervised learning and utilising a vision transformer architecture. In a recent publication in Nature, we demonstrate that RETFound performs better that other approaches for a diverse range of downstream clinical tasks, from diabetic retinopathy screening to predicting progression of age-related macular degeneration, to using the eye as a window to systemic disease (“oculomics”). We also show that RETFound is more robust on external validation, fairer across ethnicities, and more label efficient, opening the possibility of its use in less common retinal disease. We will describe the process to create this foundation model as well as our plans to scale and validate the model, going from nearly 2 million to 20 million images, and making it both 3D and truly multi-modal.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×